Heart rate

Bellabeat Unveils Next-Gen IVY Health Tracker for Women: A Leap Forward in Advanced Temperature Tracking and Wellness

Retrieved on: 
Tuesday, March 19, 2024
Research, Temperature, Health, Medicine, Frontiers Media, Menstrual cycle, IVY, Heart rate, Ovulation, Journal, Fertility, Pregnancy, Woman, Reproductive biology, Skin temperature, Machine learning, Menstruation, Map, Endocrinology, Birth control

San Francisco, California--(Newsfile Corp. - March 19, 2024) - In its latest endeavor to revolutionize women's health technology, Bellabeat has launched the new IVY+ Health Tracker.

Key Points: 
  • San Francisco, California--(Newsfile Corp. - March 19, 2024) - In its latest endeavor to revolutionize women's health technology, Bellabeat has launched the new IVY+ Health Tracker.
  • It is equipped with a sophisticated temperature tracking feature, marking a significant advancement in menstrual and fertility tracking.
  • In conjunction with the Bellabeat app, the IVY+ Health Tracker transforms biometric data into actionable wellness insights.
  • The combination of the IVY+ Health Tracker and the Bellabeat app creates a comprehensive health monitoring experience that extends beyond traditional tracking methods.

Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24

Retrieved on: 
Monday, April 8, 2024
Blood pressure, Exercise, MRCP, Patient, Heart rate, Heart, Journal, Aes, Medical Center, Quality of life, Efficacy, Heart failure, American College, HCM, Clinical trial, CPET, ACC, Pharmaceutical industry

BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to improve patient symptoms and functional capacity by enhancing cellular energetics, today announced that results from the Phase 2 IMPROVE-HCM clinical trial, evaluating ninerafaxstat in patients with symptomatic nHCM, were presented in a late-breaking clinical trial session at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.24) and published in the Journal of the American College of Cardiology (JACC).

Key Points: 
  • “We are pleased with the IMPROVE-HCM clinical trial results presented today at ACC and simultaneously published in JACC, confirming the importance of these results for patients living with nHCM,” said Anne Prener, M.D., Ph.D., president and chief executive officer of Imbria Pharmaceuticals.
  • “Based on these positive results, we plan to initiate the Phase 3 FORTITUDE-HCM clinical trial in patients with symptomatic nHCM later this year.
  • Most treatment emergent adverse events (AEs) were self-limiting and mild to moderate in severity occurring in 24 ninerafaxstat treated patients (70.6%) vs. 20 patients on placebo (60.6%).
  • improved) from 31.2 to 30.9 in the ninerafaxstat treated group and worsened from 32.7 to 34.3 in the placebo group.

Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID

Retrieved on: 
Wednesday, March 27, 2024
COVID, Type, COVID-19, Patient, Heart rate, Research, RVV, Death, Doctor of Philosophy, Trial of the century, Cough, CDC, Harvard University, Fever, Safety, Therapy, Disorder, FDA, Economics, Hospital, Pharmaceutical industry

Following the submission of the Type C meeting request package, the Company expects to hear from the FDA on a firm date for the meeting.

Key Points: 
  • Following the submission of the Type C meeting request package, the Company expects to hear from the FDA on a firm date for the meeting.
  • The CDC estimates that 7.5 percent of U.S. adults have long COVID symptoms1.
  • Currently, the Company is exploring the use of Bucillamine as a potential treatment for long COVID.
  • The Company is advancing the clinical development of Bucillamine by leveraging the published research and data from its previous Phase 3 clinical trial (the “Study”) and is finalizing the regulatory and clinical package that includes a proposed clinical study for long COVID to present to the FDA.

Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 27, 2024
Research, Blood pressure, Body composition, LDL, Adipose tissue, Obesity, Development, Cirrhosis, Three Months, Exercise, Arrhythmia, Hepatitis B virus, Diabetes, Lipid, Patient, Heart rate, Fast Track, Weight loss, Sarcopenia, MASH, Woman, Diet, Investment, Fibrosis, Safety, Optimism, FDA, Triglyceride, IMPACT, Dietary supplement

“We are extremely pleased with the results of the body composition analysis from our recently completed MOMENTUM 48-week Phase 2 obesity trial of pemvidutide.

Key Points: 
  • “We are extremely pleased with the results of the body composition analysis from our recently completed MOMENTUM 48-week Phase 2 obesity trial of pemvidutide.
  • “There is a growing appreciation that the quality of weight loss is as important as the quantity of weight loss.
  • Achieved mean weight loss of 15.6% on 2.4 mg dose of pemvidutide at week 48, with weight loss continuing at the end of treatment.
  • Financial Results for the Three Months Ended December 31, 2023
    Altimmune had cash, cash equivalents and short-term investments totaling $198.0 million at December 31, 2023.

Global Wearable Technology in Healthcare Market Analysis 2024-2029: AI-powered Medical Wearables and Epidermal Technology Emerging a Key Trends - ResearchAndMarkets.com

Retrieved on: 
Monday, April 8, 2024
Technology, Wearables, Mobile Technology, Momentum, Garmin, Health, Patient, Conditional sentence, Artificial intelligence, Miniaturization, Sennheiser, RPM, Ageing, Lilium, Application, Vital signs, Data analysis, Diabetes, Heart rate, Thermoregulation, Heart failure, Pain management, Polar Electro, Market, Privacy, Medicine, PPG, Blood pressure, Sound, Molina Healthcare, Prevalence, Pharmacy, Computer security, Research, AI, Distribution, Polar, Robotics, Preventive healthcare, Machine learning, Consumer, Temperature, Growth, Remote patient monitoring, Environment, COVID-19, Traction, Government, Rehabilitation, Medical device

The global wearable technology in healthcare market value in 2023 stood at US$42.6 billion, and is likely to reach US$169 billion by 2029.

Key Points: 
  • The global wearable technology in healthcare market value in 2023 stood at US$42.6 billion, and is likely to reach US$169 billion by 2029.
  • The global wearable technology in healthcare market value is projected to grow at a CAGR of 25.82%, during the forecast period of 2024-2029.
  • By Application: According to the report, the global wearable technology in healthcare market is bifurcated into three applications: home healthcare, sports fitness and remote patient monitoring.
  • AI-powered Medical Wearables: Integration of artificial intelligence (AI) in medical wearables enhances data analysis and insights, improving diagnostic accuracy and personalized healthcare delivery.

Pacing Toward Progress: Dr. Daniel Corcos' Trailblazing Research Reveals Exercise's Potential to Slow Parkinson's Disease Progression

Retrieved on: 
Monday, April 8, 2024
Exercise, Disease, PD, Alzheimer's disease, Risk, Patient, Heart rate, State, Observation, Parkinson's disease, Woman, Cognition, Principal investigator, Urban, Neurodegenerative disease, Pharmaceutical industry

As the second-most common neurodegenerative disease after Alzheimer's disease, PD affects nearly 90,000 individuals annually in the U.S. Globally, over 10 million people are grappling with PD.

Key Points: 
  • As the second-most common neurodegenerative disease after Alzheimer's disease, PD affects nearly 90,000 individuals annually in the U.S. Globally, over 10 million people are grappling with PD.
  • Moreover, men are 1.5 times more likely to develop Parkinson's disease than women.
  • Three recent studies, suggests that endurance exercise may offer a significant breakthrough in Parkinson's treatment in that the suggest that exercising at 80% of maximum heart rate may slow disease progression.
  • Dr. Corcos underscores the indispensable role of aerobic exercise in Parkinson's treatment, citing evidence suggesting its potential to slow disease progression.

Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID

Retrieved on: 
Tuesday, March 19, 2024
COVID, Type, COVID-19, Patient, Heart rate, Research, RVV, Death, Doctor of Philosophy, Trial of the century, Cough, CDC, Harvard University, Fever, Safety, Therapy, Disorder, FDA, Economics, Hospital, Pharmaceutical industry

The Company expects to submit the Type C meeting request by next week.

Key Points: 
  • The Company expects to submit the Type C meeting request by next week.
  • The CDC estimates that 7.5 percent of U.S. adults have long COVID symptoms1.
  • David Cutler, PhD, a professor of economics at Harvard University, estimates in a recent research disclosure that the total economic cost of long COVID could be as much as $3.7 trillion2.
  • Currently, the Company is exploring the use of Bucillamine as a potential treatment for long COVID.

Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting

Retrieved on: 
Thursday, March 14, 2024
Blood pressure, Sinai Hospital, Anaphylaxis, Absorption, Angioedema, Plasma, Type, PD, Patient, Heart rate, Adrenaline, NDA, Epinephrine autoinjector, Cmax, Trial of the century, Mouth, Therapy, Safety, Oral medicine, Allergy, Vomiting, Swelling, FDA, Study, Food, Pharmaceutical industry

“We are extremely pleased with the pivotal study results as well as our recent FDA interaction,” said Daniel Barber, President and Chief Executive Officer of Aquestive.

Key Points: 
  • “We are extremely pleased with the pivotal study results as well as our recent FDA interaction,” said Daniel Barber, President and Chief Executive Officer of Aquestive.
  • “We believe we have a clear understanding of the remaining clinical development steps necessary for a pre-NDA meeting with the FDA in the second half of the year.
  • These latest study results show that the sublingual administration of epinephrine provides rapid and sustained levels of epinephrine similar to approved treatments.
  • The FDA noted that substantial progress had been made in the Anaphylm clinical development program and did not outline any new clinical development requirements.

Revive Therapeutics Provides Corporate Update

Retrieved on: 
Tuesday, March 12, 2024
DRDC, Neuroprotection, Tremor, Diazepam, Chronic pain, COVID, Soman, National security, Survival, NAC, Seizure, Partnership, Nervous system, VX, COVID-19, Nerve agent, Patient, Brain, Heart rate, Research, Diarrhea, Endocytosis, RVV, Death, Doctor of Philosophy, Health Canada, Trial of the century, Cough, Traumatic brain injury, CDC, Harvard University, Fever, Sarin, Bleeding, Safety, Chemical warfare, Saliva, Therapy, Disorder, Blurred vision, FDA, Economics, Nerve, Hospital, Pharmaceutical industry

TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product.

Key Points: 
  • TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product.
  • Exposure to nerve agents can cause tightness of the chest, excessive salivation, abdominal cramps, diarrhea, blurred vision, tremors, and death.
  • In addition, Revive may evaluate the potential of its proposed long COVID diagnostic product as a companion to Bucillamine.
  • The Company, under its wholly-owned subsidiary Revive Diagnostics Inc., is advancing the product development of a potential blood biomarker diagnostic that characterizes long COVID.

ŌURA Introduces Oura Labs, A New In-App Innovation Hub for Members

Retrieved on: 
Wednesday, April 3, 2024
Wearables, Mobile Technology, Apps, Applications, Technology, Health Technology, Software, Hardware, Health, General Health, Data Management, Temperature, Respiratory rate, Heart rate, Oura Health, Public, Oura, Heel, Research, Sleep, Rest, University, Marketing, Radar, Fever, Citizen science, Fatigue, IOS, Feedback

ŌURA, maker of Oura Ring, the most accurate and trusted smart ring, today announced the launch of a new in-app platform, Oura Labs.

Key Points: 
  • ŌURA, maker of Oura Ring, the most accurate and trusted smart ring, today announced the launch of a new in-app platform, Oura Labs.
  • The latest addition to the Oura Membership experience is designed to accelerate innovation by bringing members into the research and development process.
  • Now, they will have the opportunity to opt-in to test experimental features, provide feedback, and contribute to discussions about Oura and the future of wearable technology.
  • Oura Members will also be able to participate in innovative research studies conducted by internal Oura teams, including Science, Product, and Marketing, as well as studies conducted in collaboration with partner organizations and academic institutions.